

QUINAZOLINE-BASED HYDROXAMIC ACIDS AS HYSTON DEACETYLASE/VGFR2 INHIBITORS


Khachatryan D.S.^a, Kolotaev A.V.^a, Balaev A.N.^b, Osipov V.N.^{a,c}

^a*NRC «Kurchatov Institute» – IREA, 107076, Russia, Moscow, Bogorodsky val, 3,
e-mail: derenik-s@yandex.ru*

^b*JSC «Pharm-Sintez», 121357, Russia, Moscow, Vereyskaya str., 29, bld. 134*

^c*N.N. Blokhin NMRC of oncology of the Health Ministry of Russia, 115478, Moscow, Kashirskoye Highway, 23*

Molecular hybridization has become a new promising way to treat cancer and neurological disorders, with a single compound that acts on multiple targets¹. Derivatives of quinazoline and hydroxamic acids are unique pharmacophore groups that are widely used in medical chemistry as drugs^{2,3}. The combination of several functional groups in one molecule can lead to a greater therapeutic effect, due to binding to several targets and possible synergistic action⁴.



The report discusses the strategy for creating bifunctional compounds by conjugating hydroxamic acids with a quinazoline moiety.

The results of work on the synthesis of new compounds containing hydroxamic acid and a heterocyclic fragment are presented.

References

1. Berube G. Expert Opinion on Drug Discovery, 2016, 11, 281.
2. Gupta S. P. Hydroxamic acids. A unique family of chemicals with multiple biological activities. – Springer-Verlag, Berlin Heidelberg, 2013. – P. 312.
3. Khan I. Bioorganic & Medicinal Chemistry. 2016, 24, 2361.
4. Hesham H.M., Lasheen D.S. Medicinal Research Reviews. 2018, 38, 2058.

This work was supported by the Ministry of Education and Science of the Russian Federation (grant agreement N 075-11-2018-172 from 03.12.18) RFMEFI62418X0051